is one of the latest innovations in androgen signalling inhibition in high-risk nmCRP
(apalutamide) summary of product characteristics. Janssen, 2018.
Janssen Pharmaceutica NV 2021. This site is published by Janssen Pharmaceutica NV which is solely responsible for its content. It is intended for European, Middle Eastern and African Healthcare professionals.